I trained as both a physician and a scientist. For decades, I practiced and taught in Medicine and built a firm that hires PhDs. The interviewer’s question probed beyond simple background focusing on a potential dichotomy. “Did those two kinds of minds ever come into conflict in the way I trade?”
You’ve decided that Macro or Trend is right for your portfolio, but now what? How do you narrow the field with so many managers and offerings? We discussed this ourselves, and here’s a short video clip to get you started.
Where can Macro contribute the most, and how might this change in the year ahead? The engines are returns, noncorrelation, and downside performance, and each contributes in essential ways.
Investors’ natural aversion to drawdowns can lead some to harmful action or inaction well-described in the field of behavioral finance. The best strategic and tactical investors harness a disciplined pursuit of value to capture the available excess return.
B. G., Opalesque Geneva In this interview, Dr. Patrick Welton, founder and CIO of Welton Investment Partners, offers his observations on the major macro themes expected to affect the commodity markets, including crude oil, and ESG investing this year. Welton is an...
Regrettably, only a fraction of published medical research is reproducible by other investigators. This is no surprise to those of us who contribute or follow medical advancements. Hundreds of reviews have documented tens of thousands of examples. From cancer...
Human versus machine. Which is superior? It’s a centuries-old question that continues to fascinate us. Regrettably, for investors, it often fascinates to the point of distraction. But, investors are only human. And when investors are both the questioner and a...
For macroeconomic investors the passage of this bill is a watershed event, but its implications for what comes next are likely even more consequential. The new $1.9T economic relief package that was passed by Congress this week and signed into law yesterday, is...